An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder

Trial Profile

An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs PF 6372865 (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Dec 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.
    • 10 Nov 2015 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top